Journal article

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study

Weiva Sieh, Martin Koebel, Teri A Longacre, David D Bowtell, Anna defazio, Marc T Goodman, Estrid Hogdall, Suha Deen, Nicolas Wentzensen, Kirsten B Moysich, James D Brenton, Blaise A Clarke, Usha Menon, C Blake Gilks, Andre Kim, Jason Madore, Sian Fereday, Joshy George, Laura Galletta, Galina Lurie Show all

LANCET ONCOLOGY | ELSEVIER SCIENCE INC | Published : 2013

Grants

Awarded by US Department of Defense


Awarded by Australian National Health and Medical Research Council


Awarded by US National Institutes of Health (NIH)


Awarded by NIH


Awarded by Danish Cancer Society


Awarded by Cancer Research UK


Awarded by The Francis Crick Institute


Awarded by DIVISION OF CANCER CONTROL &POPULATION SCIENCE


Awarded by DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS


Awarded by DIVISION OF CANCER PREVENTION AND CONTROL


Awarded by NATIONAL CANCER INSTITUTE


Funding Acknowledgements

This study was supported by the Carraresi Foundation through donations to the Vancouver General Hospital and University of British Columbia Hospital Foundation. AOC was supported by the US Department of Defense (DAMD17-01-1-0729), Cancer Council Victoria, Queensland Cancer Fund, Cancer Council New South Wales, Cancer Council South Australia, Cancer Foundation of Western Australia, Cancer Council Tasmania, Australian National Health and Medical Research Council (grants 400413 and 400281). HAW was funded by the US National Institutes of Health (NIH; grants R01CA58598, N01CN55424, N01PC67001). MAL was funded by the NIH (R01CA61107), Danish Cancer Society (94 222 52), and the Mermaid I project. MAY+MAC was funded by the NIH (grants R01CA122443 and P50CA136393), Mayo Foundation, and the Fred C and Katherine B Andersen Foundation. The Polish Ovarian Cancer Study (POL) was funded by the NIH (Z01CP010126). The Roswell Park Cancer Institute Ovarian Cancer Cohort (RPX) was funded by the Roswell Park Cancer Institute Alliance Foundation. The Study of Epidemiology and Risk Factors in Cancer Heredity (SEA) was funded by Cancer Research UK (C490/A10119 C490/A10124), National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, and the Cambridge Experimental Cancer Medicine Centre. STA was funded by the NIH (U01CA71966, U01CA69417, R01CA16056, and K07CA143047). The UK Ovarian Cancer Population Study (UKO) was funded by Eve Appeal (Oak Foundation) and was supported by researchers at the NIHR University College London Hospitals Biomedical Research Centre. VAN was funded by the British Columbia Cancer Foundation, Vancouver General Hospital and University of British Columbia Hospital Foundation, and Sanofi-Aventis Canada. We thank all the women, study centres, and personnel who participated in this study. We gratefully acknowledge the contributions of the Australian Ovarian Cancer Study Group; Karin Goodman, Ashley Pitzer, and the Mayo Clinic Medical Genome Facility; Fiona Blows and the SEARCH team; Ian Jacobs, Andy Ryan, Jeremy Ford, Nayaladzi Balogun; and the Cheryl Brown Ovarian Cancer Outcomes Unit.